|
1
|
Sarkar FH and Li Y: Harnessing the fruits
of nature for the development of multi-targeted cancer
therapeutics. Cancer Treat Rev. 35:597–607. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li F and Sethi G: Targeting transcription
factor NF-kappaB to overcome chemoresistance and radioresistance in
cancer therapy. Biochim Biophys Acta. 1805:167–180. 2010.PubMed/NCBI
|
|
3
|
Van Antwerp DJ, Martin SJ, Kafri T, Green
DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by
NF-kappaB. Science. 274:787–789. 1996.PubMed/NCBI
|
|
4
|
Cusack JC Jr, Liu R and Baldwin AS Jr:
Inducible chemoresistance to
7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin
(CPT-11) in colorectal cancer cells and a xenograft model is
overcome by inhibition of nuclear factor-kappaB activation. Cancer
Res. 60:2323–2330. 2000.PubMed/NCBI
|
|
5
|
Baldwin AS Jr: Series introduction: the
transcription factor NF-kappaB and human disease. J Clin Investig.
107:3–6. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-kappaB antiapoptosis: induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Y and Villalona-Calero MA: Irinotecan:
mechanism of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wasserman E, Sutherland W and Cvitkovic E:
Irinotecan plus oxaliplatin: a promising combination for advanced
colorectal cancer. Clin Colorectal Cancer. 1:149–153. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stahel RA and Zangemeister-Wittke U:
Antisense oligonucleotides for cancer therapy-an overview. Lung
Cancer. 41(Suppl 1): S81–S88. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah SA, Potter MW, McDade TP, Ricciardi
R, Perugini RA, Elliott PJ, Adams J and Callery MP: 26S proteasome
inhibition induces apoptosis and limits growth of human pancreatic
cancer. J Cell Biochem. 82:110–122. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cusack JC Jr, Liu R, Houston M, Abendroth
K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity
to CPT-11 with proteasome inhibitor PS-341: implications for
systemic nuclear factor-kappaB inhibition. Cancer Res.
61:3535–3540. 2001.PubMed/NCBI
|
|
12
|
Guo J, Verma UN, Gaynor RB, Frenkel EP and
Becerra CR: Enhanced chemosensitivity to irinotecan by RNA
interference-mediated down-regulation of the nuclear factor-kappaB
p65 subunit. Clin Cancer Res. 10:3333–3341. 2004. View Article : Google Scholar
|
|
13
|
Lagdec P, Griessinger E, Nawrot MP,
Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D,
Rousseau D, et al: Pharmacological targeting of NF-kappaB
potentiates the effect of the topoisomerase inhibitor CPT-11 on
colon cancer cells. Br J Cancer. 98:335–344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu S, Fang Y, Shen H, Xu W and Li H:
Berberine sensitizes ovarian cancer cells to cisplatin through
miR-21/PDCD4 axis. Acta Biochim Biophys Sin (Shanghai). 45:756–762.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pandey MK, Sung B, Kunnumakkara AB, Sethi
G, Chaturvedi MM and Aggarwal BB: Berberine modifies cysteine 179
of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated
antiapoptotic gene products, and potentiates apoptosis. Cancer Res.
68:5370–5379. 2008. View Article : Google Scholar
|
|
16
|
Papazisis KT, Geromichalos GD, Dimitriadis
KA and Kortsaris AH: Optimization of the sulforhodamine B
colorimetric assay. J Immumol Methods. 208:151–158. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al
Abdulmohsen S, Platanias LC, Al-Kuraya KS and Uddin S: Cross-Talk
between NF-κB and the PI3-Kinase/AKT pathway can be targeted in
primary effusion lymphoma (PEL) cell lines for efficient apoptosis.
PLoS One. 7:e399452012.
|
|
18
|
Hussain AR, Ahmed M, Al-Jomah NA, Khan AS,
Manogaran P, Sultana M, Abubaker J, Platanias LC, Al-Kuraya KS and
Uddin S: Curcumin suppresses constitutive activation of nuclear
factor-kappa B and requires functional Bax to induce apoptosis in
Burkitt's lymphoma cell lines. Mol Cancer Ther. 7:3318–3329. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Q, Zhang J, Liu L, Sharma S and Dong
Q: Quercetin potentiates doxorubicin mediated antitumor effects
against liver cancer through p53/Bcl-xl. PLoS One. 7:e517642012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zou Z, Xie L, Wei J, Yu L, Qian X, Chen J,
Wang T and Liu B: Synergistic anti-proliferative effects of
gambogic acid with docetaxel in gastrointestinal cancer cell lines.
BMC Complement Altern Med. 12:582012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kawano Y, Nagata M, Kohno T, Ichimiya A,
Iwakiri T, Okumura M and Arimori K: Caffeine increases the
antitumor effect of Cisplatin in human hepatocellular carcinoma
cells. Biol Pharm Bull. 35:400–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pacifico F and Leonardi A: Role of
NF-kappaB in thyroid cancer. Mol Cell Endocrinol. 321:29–35. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Baud V and Karin M: Is NF-kappaB a good
target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov.
8:33–40. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuoharczak J, Simmons MJ, Fan Y and
Gélinas C: To be, or not to be: NF-kappaB is the answer - role of
Rel/NF-kappaB in the regulation of apoptosis. Oncogene.
22:8961–8982. 2003. View Article : Google Scholar : PubMed/NCBI
|
